American Cancer Society. Cancer Facts & Figures 2018. In: Atlanta: American Cancer Society; 2018.
Google Scholar
Treatment of invasive epithelial ovarian cancers, by stage. American Cancer Society, Atlanta. 2017. https://www.cancer.org/cancer/ovarian-cancer/treating/by-stage.html. Accessed 15 Jan 2018.
Ledermann JA, Raja FA, Fotopoulou C, Gonzalez-Martin A, Colombo N, Sessa C. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24:vi24–32.
Article
Google Scholar
NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer. Version 1.2018. National Comprehensive Cancer Network, Ft. Washington, PA. 2018. Accessed 20 Apr 2018.
Markman M, Hoskins W. Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population. J Clin Oncol. 1992;10:513–4.
Article
CAS
Google Scholar
Verhaar-Langereis M, Karakus A, van Eijkeren M, Voest E, Witteveen E. Phase II study of the combination of pegylated liposomal doxorubicin and topotecan in platinum-resistant ovarian cancer. Int J Gynecol Cancer. 2006;16:65–70.
Article
CAS
Google Scholar
Salom E, Mirhashemi R, Lambrou N, Almeida Z, Auguste F. Topotecan and doxorubicin HCL liposome combination therapy in the treatment of recurrent/refractory ovarian cancer: a phase II study. Proc am Soc Clin Oncol. 2003;22:1911.
Google Scholar
Horwood K, Colosimo M, Wyld D, Abraham R, Choo PS. Crandon a. a phase II trial of gemcitabine and liposomal doxorubicin in platinum-resistant ovarian cancer (PROC). Proc Am Soc Clin Oncol. 2002;21:888.
Google Scholar
D’Agostino G, Ferrandina G, Ludovisi M, Testa A, Lorusso D, Gbaguidi N, et al. Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer. Br J Cancer. 2003;89:1180–4.
Article
Google Scholar
Campos SM, Matulonis UA, Penson RT, Lee H, Berkowitz RS, Duska LR, et al. Phase II study of liposomal doxorubicin and weekly paclitaxel for recurrent Müllerian tumors. Gynecol Oncol. 2003;90:610–8.
Article
CAS
Google Scholar
Gallego O, Monetsinos J, Losa F, Eres N, Arcusa A, Franquesa R. a phase II study of pegylated liposomal doxorubicin (PLD), and cyclophosphamide (CTX) as second line therapy in platinum resistant ovarian cancer (OC) patients. Proc am Soc Clin Oncol. 2003;22:1931.
Google Scholar
Katsaros D, Oletti MV, Rigault de la Longrais IA, Ferrero A, Celano A, Fracchioli S, et al. Clinical and pharmacokinetic phase II study of pegylated liposomal doxorubicin and vinorelbine in heavily pretreated recurrent ovarian carcinoma. Ann Oncol. 2005;16:300–6.
Article
CAS
Google Scholar
European Medicines Agency. Caelyx. https://www.ema.europa.eu/medicines/human/EPAR/caelyx#product-information-section. Accessed 3 Oct 2018.
Food US, Adminstration D. Drugs@FDA: FDA approved drug products. DOXIL (LIPOSOMAL). https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050718s051lbl.pdf. Accessed 3 Oct 2018.
Hart CE, Forstrom JW, Kelly JD, Seifert RA, Smith RA, Ross R, et al. Two classes of PDGF receptor recognize different isoforms of PDGF. Science. 1988;240:1529–31.
Article
CAS
Google Scholar
Heldin CH, Ostman A, Ronnstrand L. Signal transduction via platelet-derived growth factor receptors. Biochim Biophys Acta. 1998;1378:F79–F113.
CAS
PubMed
Google Scholar
Ostman A, Heldin CH. Involvement of platelet-derived growth factor in disease: development of specific antagonists. Adv Cancer Res. 2001;80:1–38.
Article
CAS
Google Scholar
Ng F, Boucher S, Koh S, Sastry KS, Chase L, Lakshmipathy U, et al. PDGF, TGF-beta, and FGF signaling is important for differentiation and growth of mesenchymal stem cells (MSCs): transcriptional profiling can identify markers and signaling pathways important in differentiation of MSCs into adipogenic, chondrogenic, and osteogenic lineages. Blood. 2008;112:295–307.
Article
CAS
Google Scholar
Chen CY, Liu SH, Chen CY, Chen PC, Chen CP. Human placenta-derived multipotent mesenchymal stromal cells involved in placental angiogenesis via the PDGF-BB and STAT3 pathways. Biol Reprod. 2015;93:103.
Article
Google Scholar
Choi H-J, Armaiz Pena GN, Pradeep S, Cho MS, Coleman RL, Sood AK. Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches. Cancer Metastasis Rev. 2015;34(1):19–40.
Article
CAS
Google Scholar
Lassus H, Sihto H, Leminen A, Nordling S, Joensuu H, Nupponen NN, et al. Genetic alterations and protein expression of KIT and PDGFRA in serous ovarian carcinoma. Br J Cancer. 2004;91:2048–55.
Article
CAS
Google Scholar
Wilczynski SP, Chen YY, Chen W, Howell SB, Shively JE, Alberts DS. Expression and mutational analysis of tyrosine kinase receptors c-kit, PDGFRalpha, and PDGFRbeta in ovarian cancers. Hum Pathol. 2005;36:242–9.
Article
CAS
Google Scholar
Matei D, Emerson RE, Lai YC, Baldridge LA, Rao J, Yiannoutsos C, et al. Autocrine activation of PDGFRalpha promotes the progression of ovarian cancer. Oncogene. 2006;25:2060–9.
Article
CAS
Google Scholar
Holzer TR, O’Neill Reising L, Credille KM, Schade AE, Oakley GJ. Variability in platelet-derived growth factor receptor alpha antibody specificity may impact clinical utility of immunohistochemistry assays. J Histochem Cytochem. 2016;64(12):785–810.
Article
CAS
Google Scholar
Matsuo K, Nishimura M, Komurov K, Shahzad M, Ali-Fehmi R, Roh JW, et al. Platelet-derived growth factor receptor alpha (PDGFRα) targeting and relevant biomarkers in ovarian carcinoma. Gynecol Oncol. 2014;132:166–75.
Article
CAS
Google Scholar
Matei D, Emerson RE, Schilder J, Menning N, Baldridge LA, Johnson CS, et al. Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: a Hoosier oncology group trial. Cancer. 2008;113:723–32.
Article
CAS
Google Scholar
Loizos N, Xu Y, Huber J, Liu M, Lu D, Finnerty B, et al. Targeting the platelet-derived growth factor receptor alpha with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: implications as a potential therapeutic target. Mol Cancer Ther. 2005;4:369–79.
CAS
PubMed
Google Scholar
Lowery CD, Blosser W, Dowless M, Knoche S, Stephens J, Li H, et al. Olaratumab exerts antitumor activity in preclinical models of pediatric bone and soft tissue tumors through inhibition of platelet-derived growth factor receptor α. Clin Cancer Res. 2018;24:847–57.
Article
CAS
Google Scholar
Tap WD, Jones RL, Van Tine BA, Chmielowski B, Elias AD, Adkins D, et al. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet. 2016;388:488–97.
Article
CAS
Google Scholar